TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from BioArctic AB Class B ( ($SE:BIOA.B) ) is now available.
BioArctic AB has issued 4,000 Class B shares as part of its 2019/2028 stock option program, bringing the total number of shares to 88,641,485. This issuance reflects the company’s ongoing efforts to incentivize its workforce and align their interests with corporate growth, potentially impacting its market position and stakeholder value.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a Swedish biopharmaceutical company focused on developing innovative treatments for neurodegenerative diseases. It is known for inventing Leqembi®, the first drug proven to slow the progression of Alzheimer’s disease. The company collaborates with Eisai for global commercialization and has a broad research portfolio targeting Parkinson’s disease, ALS, and Alzheimer’s disease, utilizing its proprietary BrainTransporter™ technology.
Average Trading Volume: 283,568
Technical Sentiment Signal: Buy
Current Market Cap: SEK27B
See more insights into BIOA.B stock on TipRanks’ Stock Analysis page.